Profile data is unavailable for this security.
About the company
Wockhardt Limited is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It manufactures a range of dosage forms, including sterile injectables and lyophilized products. The Company offers products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy and diabetology. The Company’s products across India includes Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. It has manufacturing and research facilities in India, United States of America and the United Kingdom and a manufacturing facility in Ireland.
- Revenue in INR (TTM)27.98bn
- Net income in INR-4.63bn
- Incorporated1999
- Employees2.74k
- LocationWockhardt LtdWockhardt TowersBandra Kurla Complex, Bandra (East)MUMBAI 400051IndiaIND
- Phone+91 2 226534444
- Fax+91 2 226523905
- Websitehttp://www.wockhardt.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aarti Drugs Ltd | 25.29bn | 1.71bn | 43.84bn | 1.50k | 25.63 | 3.42 | 19.66 | 1.73 | 18.61 | 18.61 | 274.44 | 139.40 | 1.04 | 3.35 | 3.22 | -- | 7.07 | 9.73 | 10.98 | 15.74 | 33.65 | 24.96 | 6.79 | 8.25 | 1.05 | 7.91 | 0.3056 | -- | -6.90 | 10.13 | 3.07 | 13.82 | 24.96 | -- |
| Shilpa Medicare Ltd | 11.51bn | 318.74m | 47.49bn | 1.03k | 131.96 | 2.33 | 33.96 | 4.12 | 3.68 | 3.68 | 134.51 | 208.37 | 0.3841 | 1.23 | 3.21 | -- | 1.07 | 2.84 | 1.41 | 3.65 | 64.63 | 61.37 | 2.78 | 7.03 | 0.7671 | 1.41 | 0.3424 | -- | 9.66 | 9.44 | 198.15 | -22.26 | -9.26 | -- |
| Orchid Pharma Ltd | 8.19bn | 915.95m | 50.86bn | 838.00 | 52.39 | 4.35 | 39.82 | 6.21 | 19.14 | 19.14 | 169.90 | 230.58 | 0.5897 | 1.97 | 3.99 | -- | 6.80 | -0.9734 | 8.80 | -1.40 | 40.87 | 43.32 | 11.53 | -2.40 | 2.03 | 4.68 | 0.1031 | -- | 23.05 | 6.43 | 73.59 | 5.84 | 57.79 | -- |
| Aarti Pharmalabs Ltd | 18.53bn | 2.17bn | 50.93bn | 1.40k | 23.48 | 2.90 | 17.56 | 2.75 | 23.94 | 23.94 | 204.45 | 193.89 | 0.7698 | 1.64 | 3.86 | -- | 9.01 | -- | 12.30 | -- | 44.90 | -- | 11.71 | -- | 1.01 | 18.17 | 0.1397 | -- | -4.76 | -- | 12.10 | -- | -- | -- |
| Blue Jet Healthcare Ltd | 7.12bn | 1.64bn | 66.32bn | -- | 40.48 | 7.85 | 34.57 | 9.32 | 9.44 | 9.44 | 41.04 | 48.73 | 0.7409 | 2.46 | 3.42 | -- | 17.05 | -- | 21.25 | -- | 55.82 | -- | 23.01 | -- | 2.80 | 1,257.13 | 0.00 | -- | -1.30 | -- | 2.33 | -- | -- | -- |
| Sun Pharma Advanced Research Co Ltd | 755.50m | -3.87bn | 66.80bn | 407.00 | -- | 53.12 | -- | 88.42 | -11.93 | -11.93 | 2.33 | 3.87 | 0.1123 | -- | 3.13 | -- | -57.57 | -61.70 | -85.93 | -119.31 | 62.77 | 76.08 | -512.52 | -163.40 | -- | -245.33 | 0.3414 | -- | -68.36 | -16.20 | -73.96 | -- | 15.40 | -- |
| Marksans Pharma Ltd | 21.03bn | 3.17bn | 67.32bn | 1.40k | 21.08 | -- | 17.39 | 3.20 | 7.05 | 7.05 | 46.71 | -- | -- | -- | -- | 15,024,090.00 | -- | 14.78 | -- | 19.58 | 51.88 | 50.16 | 15.21 | 13.01 | -- | 44.45 | -- | 5.49 | 24.23 | 15.20 | 44.29 | 51.89 | 6.61 | 58.49 |
| F D C Ltd | 19.43bn | 3.05bn | 70.42bn | 6.37k | 23.24 | 3.36 | 20.41 | 3.62 | 18.61 | 18.61 | 118.69 | 128.81 | 0.8077 | 1.83 | 16.19 | -- | 12.68 | 12.05 | 14.56 | 13.73 | 66.23 | 62.81 | 15.70 | 15.85 | 2.18 | 74.02 | 0.0097 | -- | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
| Neuland Laboratories Ltd. | 15.59bn | 3.00bn | 77.52bn | 1.57k | 25.83 | 6.04 | 21.55 | 4.97 | 233.89 | 233.89 | 1,214.80 | 999.78 | 0.9135 | 2.33 | 4.24 | -- | 17.59 | 9.25 | 23.58 | 12.71 | 52.92 | 47.21 | 19.25 | 11.99 | 1.33 | 28.78 | 0.0692 | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Procter & Gamble Health Ltd | 11.69bn | 2.14bn | 78.03bn | 1.41k | 36.48 | -- | 32.41 | 6.68 | 128.85 | 128.85 | 703.49 | -- | -- | -- | -- | 8,305,331.00 | -- | -- | -- | -- | 70.45 | -- | 18.31 | -- | -- | 400.33 | -- | -- | 10.34 | -- | 19.19 | -- | -- | -- |
| Strides Pharma Science Ltd | 40.51bn | -1.25bn | 79.12bn | 2.85k | -- | 3.72 | 109.66 | 1.95 | -13.86 | -7.93 | 445.06 | 231.29 | 0.6493 | 1.44 | 3.32 | -- | -2.38 | -1.68 | -4.43 | -2.97 | 59.50 | 52.74 | -3.67 | -3.36 | 0.64 | 1.07 | 0.5485 | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
| Wockhardt Ltd | 27.98bn | -4.63bn | 81.20bn | 2.74k | -- | 2.43 | -- | 2.90 | -32.04 | -32.04 | 193.86 | 218.12 | 0.365 | 1.80 | 3.95 | -- | -6.16 | -4.56 | -11.11 | -8.29 | 58.36 | 55.79 | -16.87 | -12.70 | 0.5532 | -0.1906 | 0.3915 | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
| Caplin Point Laboratories Ltd | 16.94bn | 4.57bn | 97.99bn | 777.00 | 21.54 | 4.23 | 19.03 | 5.78 | 59.90 | 59.90 | 222.01 | 304.93 | 0.6931 | 2.22 | 3.62 | -- | 18.88 | 19.83 | 21.80 | 22.82 | 57.25 | 53.99 | 27.24 | 25.39 | 4.63 | 976.47 | 0.0008 | 7.86 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 2.59 |
| Granules India Ltd | 45.06bn | 4.05bn | 101.43bn | 3.65k | 25.01 | 3.14 | 16.56 | 2.25 | 16.73 | 16.73 | 186.06 | 133.08 | 0.8645 | 1.65 | 4.66 | -- | 7.78 | 10.68 | 12.41 | 16.18 | 55.15 | 51.39 | 8.99 | 11.82 | 0.7706 | 6.13 | 0.2896 | 7.84 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Glenmark Life Sciences Ltd | 22.83bn | 4.71bn | 102.46bn | 1.82k | 21.79 | 4.39 | 19.54 | 4.49 | 38.38 | 38.38 | 186.08 | 190.35 | 0.8224 | 1.58 | 2.90 | -- | 16.96 | 18.28 | 20.43 | 30.03 | 56.11 | 53.40 | 20.62 | 20.23 | 2.85 | 401.55 | 0.0073 | -- | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Jubilant Pharmova Ltd | 67.03bn | 771.00m | 108.95bn | 1.03k | 141.87 | 2.01 | 23.97 | 1.63 | 4.85 | 4.85 | 421.25 | 343.16 | 0.5904 | 1.60 | 7.14 | -- | 0.6404 | 2.96 | 0.7627 | 3.55 | 68.06 | 69.37 | 1.08 | 5.13 | 1.37 | 2.09 | 0.4033 | 24.69 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
Data as of May 31 2024. Currency figures normalised to Wockhardt Ltd's reporting currency: Indian Rupee INR
5.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Apr 2024 | 2.22m | 1.45% |
| ICICI Prudential Asset Management Co. Ltd.as of 30 Apr 2024 | 1.93m | 1.26% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 895.53k | 0.58% |
| Invesco Asset Management (India) Pvt Ltd.as of 30 Apr 2024 | 643.44k | 0.42% |
| BlackRock Fund Advisorsas of 09 May 2024 | 554.03k | 0.36% |
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 30 Apr 2024 | 483.56k | 0.32% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 351.08k | 0.23% |
| SSgA Funds Management, Inc.as of 09 May 2024 | 277.41k | 0.18% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Apr 2024 | 232.11k | 0.15% |
| BlackRock Advisors (UK) Ltd.as of 09 May 2024 | 204.67k | 0.13% |
More ▼
Data from 31 Dec 2023 - 15 May 2024Source: FactSet Research Systems Inc.
